By NewsDesk @bactiman63
The National Administration of Medicines, Food and Medical Technology (ANMAT) authorized the use of Takeda’s dengue vaccine, Qdenga, for all people over 4 years of age, whether or not they have previously had the disease.
Qdenga is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four dengue virus serotypes and is designed to protect against any of these serotypes
Qdenga (TAK-003) was first approved in August 2022 in Indonesia and subsequently in the European Union in December 2022. It was followed by the UK in January 2023 and has recently also been approved by the National Health Surveillance Agency of Brazil (ANVISA). Its use is contemplated for endemic areas.
After the approval by the ANMAT, Takeda will establish the protocols for the start of the production process for sending a batch of it to our country. When this happens, once this cycle is completed and always following quality and traceability standards, Argentina will be in a position to receive this shipment for its subsequent commercialization in national territory.
Dengue is a mosquito-borne viral disease that poses a significant global public health threat to half the world’s population, with risk of infection in over 125 countries including many in Latin America. Severe dengue has become a leading cause of hospitalization and death among children and adults in some of the countries within the region.